TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.

Valentina Boni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.